Survival of patients with acute myelogenous leukemia (AML) depends on our ability to
prevent relapse in patients that achieved complete remission after intensive chemotherapy.
While studies focusing on the malignant clone brought many advances in understanding
AML biology and chemoresistance, little improvement has been made in eliminating the last
bastion of malignant cells, the minimal residual disease (MRD). Inspired by Sir Paget's “soil
and seed” hypothesis, it is becoming more clear that there is constant feedback between the …